News Issue · Rank #3
Moderna jumps ~13% on flu-vaccine win and pipeline update
Moderna surged about 13% after a flu-vaccine win and an upbeat pipeline narrative at its Science Day, where it highlighted an expanding mRNA platform. The move outpaced vaccine peers and reflects renewed investor interest in mRNA beyond COVID.
Key points to watch
- Shares up ~14% intraday to ~$68.23
- Flu program win plus Science Day pipeline detail
- Outperformed Merck, Pfizer on the day
- Watch upcoming flu/combo data readouts
▲ Bullish Vaccines & mRNA (Bullish)
What's the impact??
Vaccines & mRNA
BullishFlu win and platform expansion lift Moderna and refocus attention on mRNA optionality versus legacy vaccine makers.
Coverage
7 sources reporting on this issue
- Moderna (MRNA) Sees 14.2% Surge, Reaches $68.23GuruFocus
- MRNA Stock Jumps As Flu Win And Pipeline Story Heat UpStocksToTrade
- Moderna highlights expanding mRNA platform at Science DayClinical Trials Arena
Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?24/7 Wall St.
- Chip Rout Drags Nasdaq 100, Oil Sinks Below $69: Stock Market TodayBenzinga
- Biogen Jumps 6.1% Amid Sector-Wide RallyAlphaStreet
AI-estimated from multi-source news and live quotes. Sector impact is a model estimate, not a recommendation. For information only — not investment advice.